Bismuth compounds in medicinal chemistry

Future Medicinal Chemistry

Volumn 4, Issue 11, 2012, Pages 1495-1523

  Salvador, Jorge Ar ^a,b   Figueiredo, Sandra Ac ^a   Pinto, Rui Ma ^a   Silvestre, Samuel M ^c  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF BEIRA INTERIOR   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDROPYRIDINE; 2 AMINOTHIAZOLE DERIVATIVE; 4(3H) QUINAZOLINONE DERIVATIVE; AMLODIPINE; BARBITURIC ACID DERIVATIVE; BETA LACTAM ANTIBIOTIC; BETULIN; BISMUTH CITRATE; BISMUTH DERIVATIVE; BISMUTH SALT; CLARITHROMYCIN; COUMARIN DERIVATIVE; COUMATETRALYL; DIKETONE; GLYCOPROTEIN GP 120; LEVOFLOXACIN; METRONIDAZOLE; NICARDIPINE; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; OLEANOLIC ACID; PHENPROCOUMON; PLATENSIMYCIN; RADIOISOTOPE; RANITIDINE; STEROID HORMONE; TETRAHYDROFURAN; UNINDEXED DRUG; VANDETANIB; WARFARIN;

ANTIMICROBIAL ACTIVITY; CATALYST; CHEMICAL REACTION; CLINICAL EVALUATION; CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; GASTROINTESTINAL DISEASE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYPHILIS;

ANTI-INFECTIVE AGENTS; ANTI-ULCER AGENTS; ANTINEOPLASTIC AGENTS; BISMUTH; CATALYSIS; CELL PROLIFERATION; CHEMISTRY, PHARMACEUTICAL; COORDINATION COMPLEXES; HELICOBACTER PYLORI; MESYLATES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;

EID: 84864659112     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.95     Document Type: Review

References (179)

1. Mohan RS. Green bismuth. Nat. Chem. 2, 336 (2010).
2. Suzuki H. Introduction. In: Organobismuth Chemistry. Suzuki H, Matano Y (Eds). Elsevier, Amsterdam, The Netherlands, 1-20 (2001).
3. Suzuki H, Ikegami T, Matano Y. Bismuth in organic transformations. Synthesis 249-267 (1997). (Pubitemid 27201726)
4. Barton DHR, Finet JP. Bismuth(V) reagents in organic synthesis. Pure Appl. Chem. 59, 937-946 (1987).
5. Le Roux C, Dubac J. Bismuth(III) chloride and triflate: novel catalysts for acylation and sulfonylation reactions. Survey and mechanistic aspects. Synlett. 181-200 (2002). (Pubitemid 34133993)
6. Gaspard-Iloughmane H, Le Roux C. Bismuth(III) triflate in organic synthesis. Eur. J. Org. Chem. 12, 2517-2532 (2004).
7. Leonard NM, Wieland LC, Mohan RS. Applications of bismuth(III) compounds in organic synthesis. Tetrahedron 58, 8373-8397 (2002).
8. Ho TL. Hard soft acids bases (HSAB) principle and organic chemistry. Chem. Rev. 75, 1-20 (1975).
9. Gaspard-Iloughmane H, Le Roux C. Recent advances in the use of bismuth(III) triflate in organic synthesis: an update. Trends. Org. Chem. 11, 65-80 (2006).
10. Gaspard-Iloughmane H, Le Roux C. Bi(III) Lewis acids. In: Acid Catalysis in Modern Organic Chemistry. Yamamoto H, Ishihara K (Eds). John Wiley & Sons, New York, NY, USA, 551-588 (2008).
11. Peyronneau M, Arrondo C, Vendier L, Roques N, Le Roux C. An inexpensive and simple process for the preparation of antimony(III) and bismuth(III) triflates. J. Mol. Catal. A. Chem. 211, 89-91 (2004).
12. Repichet S, Zwick A, Vendier L, Le Roux C, Dubac J. A practical, cheap and environmentally friendly preparation of bismuth(III) trifluoromethanesulfonate. Tetra. Lett. 43, 993-995 (2002). (Pubitemid 34119239)
13. Antoniotti S. Bismuth(III) tris(trifluoromethan esulfonate). Synlett 15, 1566-1567 (2003).
14. Antoniotti S, Duñach E. Recent uses of bismuth derivatives in organic synthesis. Chem Inform 36(9), 679-688 (2004). (Pubitemid 38878080)
15. Hua RM. Recent advances in bismuthcatalyzed organic synthesis. Curr. Org. Synth. 5, 1-27 (2008).
16. Komatsu N. Bismuth compounds in organic transformations. In: Organobismuth Chemistry. Suzuki H, Matano Y (Eds). Elsevier, Amsterdam, The Netherlands 371-440 (2001).
17. Loh T-P, Chua G-L. Activation of reactions by Lewis acids derived from Ga, In, Sb and Bi. In: Advances in Organic Synthesis. Atta-Ur-Rahman (Eds). Bentham Science Publishers, Sharjah, UAE, 173-214 (2005).
18. Marshall JA. Organic chemistry of Bi(III) compounds. Chemtracts Org. Chem. 5, 1064-1075 (1997).
19. Mulamoottil VA. Bismuth(III) nitrate pentahydrate - a versatile reagent in organic synthesis. Synlett. 17, 2699-2700 (2005). (Pubitemid 41532204)
20. Postel M, Duñach E. Bismuth derivatives for the oxidation of organic compounds. Coord. Chem. Rev. 155, 127-144 (1996).
21. Vidal S. Bismuth(III) derivatives: new catalysts. Synlett 13, 1194-1195 (2001). (Pubitemid 32625003)
22. Bothwell JM, Krabbe SW, Mohan RS. Applications of bismuth(III) compounds in organic synthesis. Chem. Soc. Rev. 40, 4649-4707 (2011).
23. Salvador JAR, Pinto RMA, Silvestre SM. Recent advances of bismuth(III) salts in organic chemistry: application to the synthesis of aliphatics, alicyclics, aromatics, amino acids and peptides, terpenes and steroids of pharmaceutical interest. Mini-Rev. Org. Chem. 6, 241-274 (2009).
24. Salvador JAR, Pinto RMA, Silvestre SM. Recent advances of bismuth(III) salts in organic chemistry: application to the synthesis of heterocycles of pharmaceutical interest. Curr. Org. Synth. 6, 426-470 (2009).
25. Salvador JAR, Silvestre SM, Pinto RMA. Bismuth(III) reagents in steroid and terpene chemistry. Molecules 16, 2884-2913 (2011).
26. Salvador JAR, Silvestre SM, Pinto RMA. Chapter 8. Highlights of bismuth(III) salts applications in the synthesis of compounds of pharmaceutical interest. In: Bismuth: Characteristics, Production and Applications. Ghatak KP, Bhattacharya S (Eds). NovaScience Publishers, New York, NY, USA (2011).
27. Ollevier T, Nadeau E, Desyroy V. Bismuth(III) trifluoromethanesulfonate. In: Electronic Encyclopedia of Reagents For Organic Synthesis (e-EROS). Fuchs Pl (Ed.). Wiley, Chichester, UK (2009).
28. Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat. Rev. Drug Discov. 2, 296-313 (2003). (Pubitemid 37361688)
29. Kundu SK, Mahindaratne MPD, Quintero MV, Bao A, Negretea GR. One-pot reductive cyclization to anti-tumor quinazoline precursors. Arkivoc ii, 33-42 (2008).
30. Nagaiah K, Venkatesham A, Rao RS et al. Synthesis of new cis-fused tetrahydrochromeno4,3-bquinolines and their antiproliferative activity studies against MDA-MB-231 and MCF-7 breast cancer cell lines Bioorg. Med. Chem. Lett. 20, 3259-3264 (2010).
31. Kamal A, Reddy KL, Devaiah V, Shankaraiah N, Reddy DR. Recent advances in the solid-phase combinatorial synthetic strategies for the benzodiazepine based privileged structures. Mini-Rev. Med. Chem. 6, 53-69 (2006).
32. Ramajayam R, Giridhar R, Yadav MR. Current scenario of 1,4-diazepines as potent biomolecules - a mini review Mini-Rev. Med. Chem. 7, 793-812 (2007). (Pubitemid 47304941)
33. Kamal A, Reddy PSMM, Reddy DR. An efficient catalytic deprotection of thioacetals employing bismuth triflate: synthesis of pyrrolo2,1-c1, 4benzodiazepines Tetra. Lett. 44, 2857-2860 (2003). (Pubitemid 36324395)
34. Lindner A, Schmidt A. N-heterocyclic carbenes of indazole as reagents: indazol-3- ylidene-mediated syntheses of amidines from thiolactams of pyrrolobenzodiazepines. Synlett 20, 2961-2964 (2008).
35. Miao H-Q, Liu H, Navarro E, Kussie P, Zhu Z. Development of heparanase inhibitors for anti-cancer therapy. Curr. Med. Chem. 13, 2101-2111 (2006). (Pubitemid 44132602)
36. Valerio S, Pastore A, Adinolfi M, Iadonisi A. Sequential one-pot gycosidations catalytically promoted: unprecedented strategy in oligosaccharide synthesis for the straightforward assemblage of the anti-tumor PI-88 pentasaccharide. J. Org. Chem. 73, 4496-4503 (2008). (Pubitemid 351842465)
37. Green AP, Lee ATL, Thomas EJ. Total synthesis of a 20-deoxybryostatin. Chem. Commun. 47, 7200-7202 (2011).
38. Guardiola F, Dutta PC, Codony R, Savage GP. Cholesterol and phytosterol oxidation products: analysis, occurrence, and biological effects. AOCS Press, New York, NY, USA (2002).
39. Schroepfer GJ. Oxysterols: modulators of cholesterol metabolism and other processes. Physiol. Rev. 80, 361-554 (2000).
40. Carvalho JFS, Silva MMC, Melo M. Efficient trans-diaxial hydroxylation of Δ5-steroids. Tetrahedron 66, 2455-2462 (2010).
41. Dehaen W, Mashentseva AA, Seitembetov TS. Allobetulin and its derivatives: synthesis and biological activity. Molecules 47(3), 2443-2466 (2011).
42. King JF, Mayo P. Terpenoid rearrangements. In: Molecular Rearrangements. Mayo P (Ed.). Interscience Publishers, John Wiley & Sons, New York, NY, USA, 771-840 (1968).
43. Salvador JAR, Pinto RMA, Santos RC, Le Roux C, Beja AM, Paixao JA. Bismuth triflate-catalyzed Wagner-Meerwein rearrangement in terpenes. Application to the synthesis of the 18α-oleanane core and A-neo-18a-oleanene compounds from lupanes. Org. Biomol. Chem. 7, 508-517 (2009).
44. Salvador JAR, Moreira VM, Pinto RMA, Leal AS, Le Roux C. Bismuth(III) triflate-based catalytic direct opening of oleanolic hydroxy-γ-lactones to afford 12-oxo-28- carboxylic acids. Adv. Synth. Catal. 353, 2637-2642 (2011).
45. Winum J-Y, Scozzafava A, Montero J-L, Supuran CT. Therapeutic potential of sulfamides as enzyme inhibitors. Med. Res. Rev. 26, 767-792 (2006). (Pubitemid 44735553)
46. Reitz AB, Smith GR, Parker MH. The role of sulfamide derivatives in medicinal chemistry: a patent review (2006-2008). Exp. Opin. Ther. Pat. 19, 1449-1453 (2009).
47. Adibi H, Massah AR, Majnooni MB et al. Synthesis, characterization, and antimicrobial evaluation of sulfonamides containing n-acyl moieties catalyzed by bismuth(III) salts under both solvent and solvent-free conditions. Synth. Commun. 40, 2753-2766 (2010).
48. Eey ST-C, Lear MJ. A bismuth(III)-catalyzed Friedel-Crafts cyclization and stereocontrolled organocatalytic approach to (-)-platensimycin. Org. Lett. 12, 5510-5513 (2010).
49. Johnson JH, Meyers E, O'Sullivan J et al. Culpin, a novel hydroquinone antibiotic of fungal origin. J. Antibiot. 42, 1515-1517 (1989). (Pubitemid 19263979)
50. Sunasee R, Clive DLJ. A route to 1,4-disubstituted aromatics and its application to the synthesis of the antibiotic culpin. J. Org. Chem. 72, 8016-8020 (2008).
51. He HY, Williamson RT, Shen B et al. Mannopeptimycins, novel antibacterial glycopeptides from Streptomyces hygroscopicus, LL-AC98. J. Am. Chem. Soc. 124, 9729-9736 (2002).
52. Adinolfi M, Giacomini D, Iadonisi A, Quintavalla A, Valerio S. Synthesis of the mannopeptimycin disaccharide and its conjugation with 4-alkylidene-b-lactams Eur. J. Org. Chem. 17, 2895-2899 (2008).
53. Badgujar DM, Talawar MB, Asthana SN, Mahulikar PP. Novel synthesis of biologically active nitro heterocyclic compound. J. Sci. Ind. Res. 67, 54-57 (2008).
54. Schirmer RH, Krauth-Siegel RL, Schulz GE. Coenzymes and Cofactors. Dolphin D, Poulson R, Avramovic O (Eds). John Wiley and Sons, New York, NY, USA, 553-596 (1989).
55. Senturk M, Talaz O, Ekinci D, Cavdar H, Kufrevioglu OI. In vitro inhibition of human erythrocyte glutathione reductase by some new organic nitrates. Bioorg. Med. Chem. Lett. 19, 3661-3663 (2009).
56. Giridhar T, Reddy RR, Kumar AS, Mouli GVPC. Bismuth chloride mediated synthesis, antimicrobial, and anti-inflammatory activities of new 4-aryl-2-amino thiazoles. Phosphorus Sulfur Silicon Relat. Elem. 183, 2058-2072 (2008).
57. Curini M, Cravotto G, Epifano F, Giannone G. Chemistry and biological activity of natural and synthetic prenyloxycoumarins. Curr. Med. Chem. 13, 199-222 (2006).
58. Kulkami MV, Kulkarni GM, Lin C-H, Sun C-M. Recent advances in coumarins and 1-azacoumarins as versatile biodynamic agents Curr. Med. Chem. 13, 2795-2818 (2006). (Pubitemid 44509726)
59. Fylaktakidou KC, Hadjipavlou-Litina DJ, Litinas KE, Nicolaides DN. Natural and synthetic coumarin derivatives with anti-inflammatory/antioxidant activities. Curr. Pharm. Design 10, 3813-3833 (2004). (Pubitemid 39409872)
60. O'Reilly RA. Vitamin K and the oral anticoagulant drugs. Annu. Rev. Med. 27, 245-261 (1976).
61. Rueping M, Nachtsheim BJ, Sugiono E. Direct catalytic benzylation of hydroxycoumarin - efficient synthesis of warfarin derivatives and analogues. Synlett 10, 1549-1553 (2010).
62. Saini A, Sanjay K, Sandhu JS. Hantzsch reaction: recent advances in Hantzsch 1,4-dihydropyridines. J. Sci. Ind. Res. 67, 95-111 (2008).
63. Bhattia RS, Krishana P, Sureshb, Sandhub JS. Bismuth trichloride - a clean, green catalyst for the synthesis of Hantzsch 1,4-dihydropyridines (DHPs). J. Indian Chem. Soc. 87, 707-710 (2010).
64. Mashraqui SH, Karnik MA. Bismuth nitrate pentahydrate: a convenient reagent for the oxidation of Hantzsch 1,4-dihydropyridines. Synthesis 1, 713-714 (1998). (Pubitemid 28215987)
65. Rajanarendar E, Ramesh P, Srinivas M, Ramu K, Mohan G. Solid-supported synthesis of isoxazole-substituted 1,4-dihydropyridines by modified Hantzsch method and their aromatization. Synth. Commun. 36, 665-671 (2006). (Pubitemid 43247243)
66. Adibi H, Hajipour AR. A convenient and efficient protocol for oxidative aromatization of Hantzsch 1,4-dihydropyridines using benzyltriphenylphosphonium peroxymonosulfate under almost neutral reaction conditions. Bioorg. Med. Chem. Lett. 17, 1008-1012 (2007). (Pubitemid 46177612)
67. Parker JO. Drug therapy: nitrate therapy in stable angina pectoris. N. Engl. J. Med. 338, 520-531 (1998). (Pubitemid 28103137)
68. Cavdar H, Saracoglu N. Synthesis of new b-hydroxy nitrate esters as potential glycomimetics or vasodilators. Eur. J. Org. Chem. 27, 4615-4621 (2008).
69. Ekinci D, Çavdar H, Talaz O, Sentürk M, Supuran CT. NO-releasing esters show carbonic anhydrase inhibitory action against human isoforms I and II. Bioorg. Med. Chem. 18, 3559-3563 (2010).
70. Supuran CT, Scozzafava A. Carbonic anhydrases as targets for medicinal chemistry. Bioorg. Med. Chem. 15, 4336-4350 (2007). (Pubitemid 46777288)
71. Tumiatti V, Minarini A, Bolognesi ML, Milelli A, Rosini M, Melchiorre C. Tacrine derivatives and Alzheimer's disease. Curr. Med. Chem. 17, 1825-1838 (2010).
72. da Costa JS, Pisoni DS, da Silva CB, Petzhold CL, Russowsky D, Ceschi MA. Lewis acid promoted Friedländer condensation reactions between anthranilonitrile and ketones for the synthesis of tacrine and its analogues. J. Brazil. Chem. Soc. 20, 1448-1454 (2009).
73. Astudillo SL, Vallejos CG, Gutiérrez CM, de la Guarda W, Kouznetsov VV. An eficient synthesis of 2,3-diaryl-2-azabicyclooctanones via BiCl3-catalyzed three-component aza Diels-Alder reaction. Lett. Org. Chem. 5, 559-562 (2008).
74. Nicolaou KC, Carenzi GEA, Jeso V. Construction of highly functionalized medium-sized rings: synthesis of hyperforin and perforatumone model systems. Angew. Chem. Int. Ed. Engl. 44, 3895-3899 (2005). (Pubitemid 40885704)
75. Barnes PJ. How corticosteroids control inflammation: quintiles prize lecture 2005. British J. Pharmacol. 148, 245-254 (2006). (Pubitemid 43804814)
76. Fu XY, Tann CH, Thiruvengadam TK. Process improvements in the synthesis of corticosteroid 9,11b-epoxides. Org. Process Res. Dev. 5, 376-382 (2001).
77. Pinto RMA, Salvador JAR, Le Roux C, Paixão JA. Bismuth(III) triflate-catalyzed direct conversion of corticosteroids into highly functionalized 17-ketosteroids by cleavage of the C17-dihydroxyacetone side chain. J. Org. Chem. 74, 8488-8491 (2009).
78. Salvador JAR, Silvestre SM, Moreira VM. Catalytic oxidative processes in steroid chemistry: allylic oxidation, β-selective epoxidation, alcohol oxidation and remote functionalization reactions. Curr. Org. Chem. 10, 2227-2257 (2006). (Pubitemid 44679300)
79. Brunel JM, Letourneux Y. Recent advances in the synthesis of spermine and spermidine analogs of the shark aminosterol squalamine. Eur. J. Org. Chem. 20, 3897-3907 (2003).
80. Arsenou ES, Fousteris MA, Koutsourea AI, Nikolaropouls SS. 7-Keto-D5-steroids: key-molecules owning particular biological and chemical interest. Mini-Rev. Med. Chem. 3, 557-567 (2003).
81. Salvador JAR, Silvestre SM. Bismuthcatalyzed allylic oxidation using t-butyl hydroperoxide. Tetrahedron Lett. 46, 2581-2584 (2005). (Pubitemid 40386417)
82. Bajwa JS, Jiang X, Slade J, Prasad K, Repic O, Blacklock TJ. In situ generation of Et3SiBr from BiBr3 and Et3SiH and its use in preparation of dialkyl ethers. Tetrahedron Lett. 43, 6709-6713 (2002). (Pubitemid 35245878)
83. Slade JS, Vivelo JA, Parker DJ et al. A practical synthesis of the dual matrix metalloprotease/tumor necrosis factor inhibitor MMP090. Org. Process Res. Dev. 9, 608-620 (2005). (Pubitemid 41422487)
84. Wang J, Li H, Zou G, Wang L-X. Novel template-assembled oligosaccharide clusters as epitope mimics for HIV-neutralizing antibody 2G12. Design, synthesis, and antibody binding study. Org. Biomol. Chem. 5, 1529-1540 (2007). (Pubitemid 46959421)
85. Calarese DA, Lee H-K, Huang C-Y et al. Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc. Natl Acad. Sci. USA 102, 13372-13377 (2005). (Pubitemid 41420854)
86. Wang S-K, Liang P-H, Astronomo RD et al. Targeting the carbohydrates on HIV-1: interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN. Proc. Natl Acad. Sci. USA 105, 3690-3695 (2008). (Pubitemid 351723459)
87. Pastore A, Adinolfi M, Iadonisi A, Valerio S. One-pot catalytic glycosidation/Fmoc removal - an iterable sequence for straightforward assembly of oligosaccharides related to HIV gp120. Eur. J. Org. Chem., 711-718 (2010).
88. Pastore A, Adinolfi M, Iadonisi A, Valerio S. Rapid assembly of gp120 oligosaccharide moieties via one-pot glycosidation- deprotection sequences. Carbohydr. Res. 345, 1316-1323 (2010).
89. Zingg J-M. Molecular and cellular activities of vitamin E analogues. Mini-Rev. Med. Chem. 7, 545-560 (2007). (Pubitemid 46845803)
90. Bonrath W, Dittel C, Giraudi L, Netscher T, Pabst T. Rare earth triflate catalysts in the synthesis of Vitamin E and its derivatives. Catal. Today 121, 65-70 (2007). (Pubitemid 46420309)
91. Bismuth-mediated organic reactions. In: Topics in Current Chemistry (Volume 331). Ollevier T (Ed.). Springer-Verlag, Berlin, Germany (2012).
92. Kwie FHA, Baudoin-Dehoux C, Blonski C, Lherbet C. Bismuth(III) triflate: a safe and easily handled precursor for triflic acid: application to the esterification reaction. Synth. Commun. 40, 1082-1087 (2010).
93. Ge H-M, Yang W-H, Zhang J, Tan R-X. Antioxidant oligostilbenoids from the stem wood of Hopea hainanensis. J. Agr. Food Chem. 57, 5756-5761 (2009).
94. Ge HM, Huang B, Tan SH, Shi DH, Song YC, Tan RX. Bioactive oligostilbenoids from the stem bark of Hopea exalata. J. Nat. Prod. 69, 1800-1802 (2006). (Pubitemid 46144980)
95. Yamada M, Hayashi K-i, Ikeda S et al. Inhibitory activity of plant stilbene oligomers against DNA topoisomerase II. Biol. Pharm. Bull. 29, 1504-1507 (2006).
96. Dai JR, Hallock YF, Cardellina II JH, Boyd MR. HIV-inhibitory and cytotoxic oligostilbenes from the leaves of Hopea malibato. J. Nat. Prod. 61, 351-353 (1998). (Pubitemid 28160723)
97. Huang K-S, Lin M, Cheng G-F. Antiinflammatory tetramers of resveratrol from the roots of Vitis amurensis and the conformations of the seven-membered ring in some oligostilbenes Phytochemistry 58, 357-362 (2001). (Pubitemid 32847320)
98. Kim I, Choi J. A versatile approach to oligostilbenoid natural products - synthesis of permethylated analogues of viniferifuran, malibatol A, and shoreaphenol. Org. Biomol. Chem. 7, 2788-2795 (2009).
99. Nakamura M, Niiyama K, Yamakawa T. Versatile method for the synthesis of 4-substituted 6-methyl-3-oxabicyclo3.3.1 non-6-ene-1-methanol derivatives: prins-type cyclization reaction catalyzed by hafnium triflate. Tetrahedron Lett. 50, 6462-6465 (2009).
100. Sans RG, Chozas MG. Historical aspects and applications of barbituric acid derivatives - a review. Pharmazie 43, 827-829 (1988). (Pubitemid 19042365)
101. Chebib M, Johnston GAR. GABA-activated ligand gated ion channels: Medicinal chemistry and molecular biology. J. Med. Chem. 43, 1427-1447 (2000). (Pubitemid 30238425)
102. Khan KM, Ali M, Ajaz A, Perveen S, Choudhary MI, Rahman A-U. Synthesis of 5-arylidene barbiturates: a novel class of DPPH radical scavengers. Lett. Drug Des. Discov. 5, 286-291 (2008). (Pubitemid 351840270)
103. Tanaka K, Chen X, Yoneda F. Oxidation of thiol with 5-arylidene-1,3- dimethylbarbituric acid: application to synthesis of unsymmetrical disulfide. Tetrahedron 44, 3241-3249 (1988).
104. Tanaka K, Chen X, Kimura T, Yoneda F. 5-arylidene 1,3-dimethylbarbituric acid derivatives, mild organic oxidants for allylic and benzylic alcohols. Chem. Pharm. Bull. 36, 60-69 (1988).
105. Tietze LF, Brand S, Brumby T, Fennen J. Intramolecular hetero Diels-Alder reactions of oxadienes: influence of substituents of the ether on the diastereoselectivity. Angew. Chem. Int. Ed. Engl. 29, 665-667 (1990).
106. Tietze LF, Beifuss U, Lökös M, Rischer M, Göhrt A, Scheldrick GM. Synthesis of enantiomerically pure heterosteroids by intramolecular hetero Diels-Alder reaction Angew. Chem. Int. Ed. Engl. 29, 527-529 (1990).
107. Khan KM, Ali M, Farooqui TA, Khan M, Taha M, Perveen S. An improved method for the synthesis of 5-arylidene barbiturates using BiCl3. J. Chem. Soc. Pak. 31, 823-828 (2009).
108. Juergens UR, Dethlefsen U, Steinkamp G, Gillissen A, Repges RHV. Anti-inflammatory activity of 1.8-cineol (eucalyptol) in bronchial asthma: a double-blind placebo-controlled trial. Respir. Med. 97, 738-742 (2003).
109. Kehrl W, Sonnemann U, Dethlefsen U. Therapy for acute nonpurulent rhinosinusitis with cineole: results of a double-blind, randomized, placebo-controlled trial. Laryngoscope 114, 738-742 (2004). (Pubitemid 38548789)
110. Moteki H, Hibasami H, Yamada Y, Katsuzaki H, Imai K, Komiya T. Specific induction of apoptosis by 1,8-cineole in two human leukemia cell lines, but not a in human stomach cancer cell line. Oncol. Rep. 9, 757-760 (2002).
111. Kelly BD, Allen JM, Tundel RE, Lambert TH. Multicatalytic synthesis of complex tetrahydrofurans involving bismuth(III) triflate catalyzed intramolecular hydroalkoxylation of unactivated olefins. Org. Lett. 11, 1381-1383 (2009).
112. Sun H: Biological Chemistry of Arsenic, Antimony and Bismuth. John Wiley & Sons Ltd, Singapore (2011).
113. Ahmad S, Isab AA, Ali S, Al-Arfaj AR. Perspectives in bioinorganic chemistry of some metal based therapeutic agents. Polyhedron 25, 1633-1645 (2006).
114. Briand GG, Burford N. Bismuth compounds and preparations with biological or medicinal relevance. Chem. Rev. 99, 2601-2657 (1999).
115. Sun HZ, Li HY, Sadler PJ. The biological and medicinal chemistry of bismuth. Chem. Ber. Rec. 130, 669-681 (1997). (Pubitemid 127749668)
116. Sigel A. Bismuth in medicine. In: Metal Ions in Biological Systems, Volume 41: Metal Ions and Their Complexes in Medication. CRC Press, London, UK, 333-378 (2004).
117. Tiekink ERT. Antimony and bismuth compounds in oncology. Crit. Rev. Oncol. Hematol. 42, 217-224 (2002). (Pubitemid 34618518)
118. Li H, Sun H. Recent advances in bioinorganic chemistry of bismuth. Curr. Opin. Chem. Biol. 16, 74-83 (2012).
119. Ge RG, Sun HZ. Bioinorganic chemistry of bismuth and antimony: Target sites of metallodrugs. Acc. Chem. Res. 40, 267-274 (2007).
120. Yang N, Sun H. Biological chemistry of antimony and bismuth. In: Biological Chemistry of Arsenic, Antimony and Bismuth. Sun H (Ed.). John Wiley & Sons Ltd, Singapore (2011).
121. Silvestru C, Breunig HJ, Althaus H. Structural chemistry of bismuth compounds. I. Organobismuth derivatives. Chem. Rev. 99, 3277-3327 (1999). (Pubitemid 129583054)
122. Mendis AHW, Marshall BJ. Helicobacter pylori and bismuth. In: Biological Chemistry of Arsenic, Antimony and Bismuth. Sun H (Ed.). John Wiley & Sons Ltd, Singapore (2011).
123. Li W, Jin L, Zhu N, Hou X, Deng F, Sun H. Structure of colloidal bismuth subcitrate (CBS) in dilute HCl: unique assembly of bismuth citrate dinuclear units (Bi(cit)2Bi2-). J. Am. Chem. Soc. 125, 2408-12409 (2003).
124. Andrews PC, Deacon GB, Forsyth CM, Junk PC, Kumar I, Maguire M. Towards a structural understanding of the anti-ulcer and anti-gastritis drug bismuth subsalicylate. Angew. Chem. Int. Ed. Engl. 45, 5638-5642 (2006). (Pubitemid 44366766)
125. Chey WD, Wong BCY. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am. J. Gastroenterol. 102(8), 1808-1825 (2007). (Pubitemid 47206706)
126. Malfertheiner P, Megraud F, O'Morain C. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56, 772-781. (2007). (Pubitemid 46854190)
127. Malfertheiner P, Bazzoli F, Delchier JC et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, noninferiority, Phase 3 trial. Lancet 377, 905-913 (2011).
128. Tsang C-N, Ho K-S, Sun H, Chan W-T. Tracking Bismuth anti-ulcer drug uptake in single Helicobacter pylori cells. J. Am. Chem. Soc. 133, 7355-7357 (2011).
129. Ge R, Sun X, Gu Q et al. A proteomic approach for the identification of bismuthbinding proteins in Helicobacter pylori. J. Biol. Inorg. Chem. 12, 831-842 (2007). (Pubitemid 47174873)
130. Cun S, Sun H. A zinc-binding site by negative selection induces metallodrug susceptibility in an essential chaperonin. Proc. Natl Acad. Sci. USA 107, 4943-4948 (2010).
131. Chen R, So MH, Yang J, Deng F, Che C-M, Sun H. Fabrication of bismuth subcarbonate nanotube arrays from bismuth citrate Chem. Commun. 2265-2267 (2006). (Pubitemid 43800894)
132. Chen R, Cheng G, So MH et al. Bismuth subcarbonate nanoparticles fabricated by water-in-oil microemulsion-assisted hydrothermal process exhibit anti-Helicobacter pylori properties. Mat. Res. Bull. 45, 654-658 (2010).
133. Shaikh AR, Giridhar R, Megraud F, Yadav MR. Metalloantibiotics: synthesis, characterization and antimicrobial evaluation of bismuth- fluoroquinolone complexes against Helicobacter pylori. Acta Pharm. 59, 259-271 (2009).
134. Andrews PC, Ferrero RL, Junk PC et al. Bismuth(III) complexes derived from non-steroidal anti-inflammatory drugs and their activity against Helicobacter pylori. Dalton Trans. 39, 2861-2868 (2010).
135. Andrews PC, Deacon GB, Ferrero RL et al. Bismuth(III) 5-sulfosalicylate complexes: structure, solubility and activity against Helicobacter pylori. Dalton Trans. 6377-6384 (2009).
136. Andrews PC, Busse M, Deacon GB et al. Structural and solution studies of phenylbismuth(III) sulfonate complexes and their activity against Helicobacter pylori. Dalton Trans. 39, 9633-9641 (2010).
137. Kotani T, Nagai D, Asahi K et al. Antibacterial properties os some cyclic organobismuth(III) compounds. Antimicrob. Agents Chemother. 49, 2729-2734 (2005). (Pubitemid 40917585)
138. Chauhan HPS, Shaik NM, Singh UP. Synthetic, spectroscopy and antimicrobial studies of bis(dialkyldithiocarbamato) diorganodithiophosphato bismuth(III) complexes. Appl. Organomet. Chem. 19, 1132-1139 (2005). (Pubitemid 41494311)
139. Chauhan HPS, Shaik NM, Singh UP. Synthesis, spectroscopy characterization and in vitro studies of antimicrobial activity of bis(diorganodithiocarbamato) organodithioca rbonatobismuth(III) complexes. Appl. Organomet. Chem. 20, 142-148 (2006). (Pubitemid 43163908)
140. Chauhan HPS, Bakshi A, Bhatiya S. Synthetic, spectral as well as in vitro antimicrobial studies on some bismuth(III) bis(N,N-dialkyldithiocarbamato) alkylenedithiophosphates. Appl. Organomet. Chem. 24, 317-325 (2010).
141. Solanki JS, Tripathi UN, Bhardwaj A, Thapak TR. Synthesis, spectral study and antimicrobial activity of bismuth(III) 3(2́-hydroxyphenyl)-5-(4- substituted phenyl) pyrazolinates. J. Coord. Chem. 61, 4025-4032 (2008).
142. Solanki JS, Thapak TR, Bhardwaj A, Tripathi UN. Synthesis, structural characterization, and in vitro antimicrobial properties of salicylate and pyrazoline complexes of bismuth(III). J. Coord. Chem. 64, 369-376 (2011).
143. Dawara L, Singh RV. Microwave-assisted synthesis, characterization, antimicrobial, and pesticidal activity of bismuth and antimony complexes with coumarin-based ligands. J. Coord. Chem. 64, 931-941 (2011).
144. Shaikh AR, Giridhar R, Yadav MR. Bismuth-norfloxacin complex: synthesis, physicochemical and antimicrobial evaluation. Int. J. Pharm. 332, 24-30 (2007). (Pubitemid 46227784)
145. Halwani M, Blomme S, Suntres ZE et al. Liposomal bismuth-ethanedithiol formulations enhaces antimicrobial activity of tobramycin. Int. J. Pharm. 358, 278-284 (2008).
146. Alipour M, Suntres ZE, Lafrenie RM, Omri A. Attenuation of Pseudomonas aeruginosa virulence factors and biofilms by coencapsulation of bismuth-ethanedithiol with tobramycin in liposomes. J. Antimicrob. Chemother. 65, 684-693 (2010).
147. Halwani M, Hebert S, Suntres ZE, Lafrenie RM, Azghani AO, Omri A. Bismuth-thiol incorporation enhaces biological activities of liposomal tobramycin against bacterial biofilms and quorum sensing molecules production by Pseudomonas aeruginosa. Int. J. Pharm. 373, 141-146 (2009).
148. Murafuji T, Miyoshi Y, Ishibashi M et al. Antifungal activity of organobismuth compounds against the yeast Saccharomyces cerevisiae: structure-activity relationship. J. Inorg. Biochem. 98, 547-552 (2004). (Pubitemid 38264271)
149. Murafuji T, Fujiwara Y, Yoshimatsu D, Miyakawa I, Migita K, Mikata Y. Bismuth heterocycles based on a diphenyl sulfone scaffold: synthesis and substituent effect on the antifungal activity against Saccharomyces cerevisiae. Eur. J. Med. Chem. 46, 519-525 (2010).
150. Sousa MC, Poiares da Silva J. Cytotoxicity induced by bismuth subcitrate in Giardia lamblia trophozoites. Toxicol. In Vitro 13, 591-598 (1999). (Pubitemid 29354183)
151. Gabbiani C, Messori L, Cinellu MA et al. Outstanding plasmodicidal properties within a small panel of metallic compounds: Hints for the development of new metal-based antimalarials. J. Inorg. Biochem. 103, 310-312 (2009).
152. Andrews PC, Frank R, Junk PC, Kedzierski L, Kumar I, MacLellan JG. Anti- Leishmanial activity of homo- and heteroleptic bismuth(III) carboxylates. J. Inorg. Biochem. 105, 454-461 (2011).
153. Yang N, Tanner JA, Zheng B-J et al. Bismuth complexes inhibit the SARS coronavirus. Angew. Chem. Int. Ed. Engl. 46, 6464-6468 (2007). (Pubitemid 47340173)
154. Yang N, Tanner JA, Wang Z et al. Inhibition of SARS coronavirus helicase by bismuth complexes. Chem. Commun., 4413-4415 (2007) (Pubitemid 351223616)
155. Tiekink ERT. Anticancer activity of molecular compounds of arsenic, antimony and bismuth. In: Biological Chemistry of Arsenic, Antimony and Bismuth. Sun H (Ed.). John Wiley & Sons Ltd, Singapore (2011).
156. Gulea A, Poirier D, Roy J et al. In vitro antileukemia, antibacterial and antifungal activities of some 3d metal complexes: Chemical synthesis and structure-activity relationships. J. Enz. Inhib. Med. Chem. 23, 806-818 (2008).
157. Lukevics E, Zaruma D, Ashaks J et al. Synthesis and cytotoxicity of methyl- and methoxy-substituted metal 8-quinolinethiolates. Chem. Heterocycl. Compd 44, 559-564 (2008).
158. Li H, Lai CS, Wu J, Ho PC, de Vos D, Tiekink ERT. Cytotoxicity, qualitative structureactivity relationship (QSAR), and anti-tumor activity of bismuth dithiocarbamate complexes. J. Inorg. Biochem. 101, 809-816 (2007). (Pubitemid 46529003)
159. Iuchi K, Hatano Y, Yagura T. Heterocyclic organobismuth(III) induces apoptosis of human promyelocytic leukemic cells through activation of caspases and mitochondrial perturbation. Biochem. Pharmacol. 76, 974-986 (2008).
160. Iuchi K, Akagi K, Yagura T. Heterocyclic organobismuth(III) compound targets tubulin to induce G2/M arrest in HeLa cells. J. Pharmacol. Sci. 109, 573-582 (2009).
161. Zhang X-W, Xia J, Yan H-W et al. Synthesis, structure, and in vitro antiproliferative activity of cyclic hypervalent organobismuth(III) chlorides and their triphenylgermylpropionate derivatives. J. Organomet. Chem. 694, 3019-3026 (2009).
162. Brechbiel MW. Targeted a-therapy: past, present, future? Dalton Trans. 4918-4928 (2007).
163. Kim YS, Brechbiel MW. An overview of targeted alpha therapy. Tumor Biol. 33(3), 573-590 (2012).
164. Brechbiel MW, Gansow OA. Synthesis of C-functionalized trans-cyclohexyldiethylenetri aminepenta-acetic acids for labelling of monoclonal antibodies with the bismuth-212 a-particle emitter. J. Chem. Soc. Perkin Trans. 1, 1173-1178 (1992).
165. Ma D, McDevitt MR, Finn RD, Scheinberg DA. Rapid preparation of short-lived alpha particle emitting radioimmunopharmaceuticals. Appl. Rad. Isotopes 55, 463-470 (2011).
166. Milenic DE, Garmestani k, Chappell LL et al. In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. Nuclear Medicine Biol. 29, 431-442 (2002). (Pubitemid 34597115)
167. Wu C, Kobayashi H, Sun B et al. Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans-CyDTPA. Bioorg. Med. Chem. 5, 1925-1934 (1997). (Pubitemid 27469616)
168. Milenic DE, Brady ED, Garmestani K, Albert PS, Abdulla A, Brechbiel MW. Improved efficacy of alpha-particle-targeted radiation therapy: dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72. Cancer 166, 1059-1066 (2010).
169. Seidl C, Port M, Apostolidis C et al. Differential gene expression triggered by highly cytotoxic α-emitter-immunoconjugates in gastric cancer cells. I. Invest. New Drugs 28, 49-60 (2010).
170. Seidl C, Zöckler C, Beck R, Quintanilla- Martinez L, Bruchertseifer F, Senekowitsch- Schmidtke R. 177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Biimmunotherapy, but causes toxicity not observed with 213Bi. Eur. J. Nucl. Med. Mol. Imaging 38, 312-322 (2011).
171. Wild D, Frischknecht M, Zhang H et al. Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN). Cancer Res. 71, 1009-1018 (2011).
172. Park SI, Shenoi J, Pagel JM et al. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. Blood 116, 4231-4239 (2010).
173. Pagel JM, Kenoyer AL, Bäck T et al. Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model. Blood 118, 703-711 (2011).
174. Jurcic JG, Larson SM, Sgouros G et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 100, 1233-1239 (2002). (Pubitemid 34864277)
175. Rosenblat TL, McDevitt MR, Mulford DA et al. Sequential cytarabine and alphaparticle immunotherapy with bismuth-213- lintuzumab (HuM195) for acute myeloid leukemia. Clin. Cancer Res. 16, 5303-5311 (2010).
176. Allen BJ, Raja C, Rizvi S et al. Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biol. Ther. 4, 1318-1324 (2005). (Pubitemid 43131174)
177. Allen BJ, Singla AA, Rizvi SM et al. Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma. Immunother. 3, 1041-1050 (2011).
178. Raja C, Graham P, Abbas Rizvi SM et al. Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma. Cancer Biol. Ther. 6, 846-852 (2007). (Pubitemid 351574972)
179. Cordier D, Forrer F, Bruchertseifer F et al. Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-Thi8,Met(O2) 11-substance P: a pilot trial. Eur. J. Nucl. Med. Mol. Imaging 37, 1335-1344 (2010).